

Circulating tumor DNA (ctDNA) next generation sequencing (NGS): Molecular prescreening for tailoring treatment in clinical trials

Guzmán Alonso¹, Susana Aguilar¹, F.J. Ros Montana¹, Helena Verdaguer¹, Ana Callejo Pérez¹, Irene Brana¹, Iosune Baraibar Argota¹, Patricia Iranzo Gómez¹, Omar Saavedra Santa Gadea¹, Francesc Salva Ballabrera¹, Daniel Acosta¹, Maria Vieto Villar¹, Esmeralda Garcia Torralba², Natassia Ann Worham¹, Iris Faull³, Josep Tabernero¹, Enriqueta Felip¹, Elena Elez¹, Teresa Macarulla Mercade¹, Elena Garralda¹

1 Vall d'Hebron Institute of Onocology (VHIO). Barcelona (Spain), 2 Hospital General Universitario Morales Meseguer. Murcia (Spain), 3 Medical Affairs and Business Development. Guardant Health Inc.

Vall d'Hebron


#102

Background

CtDNA NGS analysis has the potential to identify patients (pts) with the appropriate genomic alterations for enrollment in clinical trials (CT), helping overcome challenge of tissue biopsies.

Methods

Guardant360™ (G360) was performed in pts who were candidates for CT at Vall d'Hebron Institute of Oncology. Genomic alteration actionability was classified according to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). Our main objective was to analyze the targetable genomic alterations detected from all informative G360 tests, and evaluate pts inclusion in CT.





Results


108 patients were included from November 2019 to April 2021. G360 was informative in 96 pts (88,88%) and 36 pts (33,3%) had a previous tissue NGS result. Median Turn Around Time (TAT) for G360 was 8,5 days (7-15).


Patients' characteristics	All N= 108
Age Median (range)	58 (32-83)
Sex	
- Male	51 (47.22%)
- Female	57 (52.77%)
Diagnosis	
- New	31 (28.70%)
- Relapsed	77 (71.29%)
Lines of treatment median (range)	2 (0-7)
Histology	
- Colorectal	52 (48.14%)
- Pancreatic	30 (27.78%)
- NSCLC	17 (15.74%)
- Salivary Gland	4 (3.70%)
- Cholangiocarcinoma	2 (1.85%)
- Thyroid	2 (1.85%)
- Parathyroid	1 (0.92%)


Potentially targetable alterations were identified in 14 pts (14,58%); 5 pts (4,16%) with tier I variants and 9 pts (9,37%) with tier II variants. 5 pts (5,20%) received treatment based on the G360 report. 4/5 pts were treated in a CT, and 3 pts achieved a partial response. We identified 46 tier III variants that could be potential targets in phase 1 trials. Moreover, 22/52 pts (42,30%) with CRC showed RAS resistant mutations to anti-EGFR therapies.











Conclusions

G360 has a short turnaround time and is able to identify targetable alterations in patients with unknown genomic drivers. NGS of ctDNA can optimize CT recruitment.

ACKNOWLEDGEMENTS

The project that gave rise to these results has received funding from "la Caixa" Foundation under the grant agreement LCF/PR/CE07/50610001

This project has received support from Guardant Health Inc.

DISCLOSURES

The principal author declares no conflicts of interest